Skip to main content
Top
Published in: Clinical & Experimental Metastasis 5/2007

01-09-2007 | Original Paper

Specific isolation of disseminated cancer cells: a new method permitting sensitive detection of target molecules of diagnostic and therapeutic value

Authors: Siri Tveito, Gunhild M. Maelandsmo, Hanne K. Hoifodt, Heidi Rasmussen, Oystein Fodstad

Published in: Clinical & Experimental Metastasis | Issue 5/2007

Login to get access

Abstract

Molecular studies of rare cells, such as circulating cancer cells, require efficient pre-enrichment steps to obtain a pure population of target cells for further characterization. We have developed a two-step approach, starting with immunomagnetic enrichment, followed by specific isolation of individual, easily identifiable bead-rosetted target cells using a new semi-automated CellPick system. With this procedure, 1–50 live target cells can now be isolated. As a model system, we spiked a small number of tumor cells into millions of normal mononuclear cells (MNCs). Efficient isolation of pure target cells was obtained by use of the CellPick system, and the nature of isolated, bead-rosetted cells was verified by use of FISH. Single breast cancer cells were picked directly into an RNA preserving lysis buffer, reverse transcribed, and PCR amplified with two cDNA specific primer sets. With the isolated cells we consistently obtained both ubiquitously expressed and tumor cell specific PCR products. We also performed a successful mutation analysis of single cells using PCR and cycling temperature capillary electrophoresis (CTCE). This may have significant clinical implications in cancer and in other diseases, e.g. in characterizing micrometastatic cancer cells in blood and lymph nodes to help identifying patients who most likely will respond to therapies like tyrosine kinase inhibitors and compounds targeting specific mutations. By use of the CellPick system it is possible to specifically isolate bead-rosetted or otherwise labelled target cells from a heterogeneous cell population for further molecular characterization.
Literature
1.
go back to reference Fidler IJ (1970) Metastasis: guantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2′-deoxyuridine. J Natl Cancer Inst 45(4):773–782PubMed Fidler IJ (1970) Metastasis: guantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2′-deoxyuridine. J Natl Cancer Inst 45(4):773–782PubMed
2.
go back to reference Luzzi KJ, MacDonald IC, Schmidt EE, et al. (1998) Multistep nature of metastatic inefficiency:dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 153(3):865–873PubMed Luzzi KJ, MacDonald IC, Schmidt EE, et al. (1998) Multistep nature of metastatic inefficiency:dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 153(3):865–873PubMed
3.
go back to reference Wiedswang G, Borgen E, Karesen R, et al. (2003) Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 21(18):3469–3478PubMedCrossRef Wiedswang G, Borgen E, Karesen R, et al. (2003) Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 21(18):3469–3478PubMedCrossRef
4.
go back to reference Braun S, Vogl FD, Naume B, et al. (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353(8):793–802PubMedCrossRef Braun S, Vogl FD, Naume B, et al. (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353(8):793–802PubMedCrossRef
5.
go back to reference Bruland OS, Hoifodt H, Saeter G, et al. (2005) Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res 11(13):4666–4673PubMedCrossRef Bruland OS, Hoifodt H, Saeter G, et al. (2005) Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res 11(13):4666–4673PubMedCrossRef
6.
go back to reference Faye RS, Aamdal S, Hoifodt HK, et al. (2004) Immunomagnetic detection and clinical significance of micrometastatic tumor cells in malignant melanoma patients. Clin Cancer Res 10(12 Pt 1):4134–4139PubMedCrossRef Faye RS, Aamdal S, Hoifodt HK, et al. (2004) Immunomagnetic detection and clinical significance of micrometastatic tumor cells in malignant melanoma patients. Clin Cancer Res 10(12 Pt 1):4134–4139PubMedCrossRef
7.
go back to reference Cristofanilli M, Budd GT, Ellis MJ, et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781–791PubMedCrossRef Cristofanilli M, Budd GT, Ellis MJ, et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781–791PubMedCrossRef
8.
go back to reference Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10(8):789–799PubMedCrossRef Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10(8):789–799PubMedCrossRef
9.
go back to reference Slamon DJ, Godolphin W, Jones LA, et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712PubMedCrossRef Slamon DJ, Godolphin W, Jones LA, et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712PubMedCrossRef
10.
go back to reference Fidler IJ, Kripke ML (1977) Metastasis results from preexisting variant cells within a malignant tumor. Science 197 (4306):893–895PubMedCrossRef Fidler IJ, Kripke ML (1977) Metastasis results from preexisting variant cells within a malignant tumor. Science 197 (4306):893–895PubMedCrossRef
11.
go back to reference Fidler IJ, Talmadge JE (1986) Evidence that intravenously derived murine pulmonary melanoma metastases can originate from the expansion of a single tumor cell. Cancer Res 46(10):5167–5171PubMed Fidler IJ, Talmadge JE (1986) Evidence that intravenously derived murine pulmonary melanoma metastases can originate from the expansion of a single tumor cell. Cancer Res 46(10):5167–5171PubMed
12.
go back to reference Talmadge JE, Wolman SR, Fidler IJ (1982) Evidence for the clonal origin of spontaneous metastases. Science 217(4557):361–363PubMedCrossRef Talmadge JE, Wolman SR, Fidler IJ (1982) Evidence for the clonal origin of spontaneous metastases. Science 217(4557):361–363PubMedCrossRef
13.
go back to reference Fodstad O, Faye R, Hoifodt HK, et al. (2001) Immunobead-based detection and characterization of circulating tumor cells in melanoma patients. Recent Results Cancer Res 158:40–50PubMed Fodstad O, Faye R, Hoifodt HK, et al. (2001) Immunobead-based detection and characterization of circulating tumor cells in melanoma patients. Recent Results Cancer Res 158:40–50PubMed
14.
go back to reference Flatmark K, Bjornland K, Johannessen HO, et al. (2002) Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients. Clin Cancer Res 8(2):444–449PubMed Flatmark K, Bjornland K, Johannessen HO, et al. (2002) Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients. Clin Cancer Res 8(2):444–449PubMed
15.
go back to reference Fodstad O, Kjonniksen I, Aamdal S, et al. (1988) Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells. Cancer Res 48(15):4382–4389PubMed Fodstad O, Kjonniksen I, Aamdal S, et al. (1988) Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells. Cancer Res 48(15):4382–4389PubMed
16.
go back to reference Yamamoto N, Yang M, Jiang P, et al. (2004) Color coding cancer cells with fluorescent proteins to visualize in vivo cellular interaction in metastatic colonies. Anticancer Res 24(6):4067–4072PubMed Yamamoto N, Yang M, Jiang P, et al. (2004) Color coding cancer cells with fluorescent proteins to visualize in vivo cellular interaction in metastatic colonies. Anticancer Res 24(6):4067–4072PubMed
17.
go back to reference Bjornland K, Flatmark K, Mala T, et al. (2003) Detection of disseminated tumour cells in bone marrow of patients with isolated liver metastases from colorectal cancer. J Surg Oncol 82(4):224–227PubMedCrossRef Bjornland K, Flatmark K, Mala T, et al. (2003) Detection of disseminated tumour cells in bone marrow of patients with isolated liver metastases from colorectal cancer. J Surg Oncol 82(4):224–227PubMedCrossRef
18.
go back to reference Imai K, Wilson BS, Bigotti A, et al. (1982) A 94,000-dalton glycoprotein expressed by human melanoma and carcinoma cells. J Natl Cancer Inst 68(5):761–769PubMed Imai K, Wilson BS, Bigotti A, et al. (1982) A 94,000-dalton glycoprotein expressed by human melanoma and carcinoma cells. J Natl Cancer Inst 68(5):761–769PubMed
19.
go back to reference Hinselwood DC, Abrahamsen TW, Ekstrom PO (2005) BRAF mutation detection and identification by cycling temperature capillary electrophoresis. Electrophoresis 26(13):2553–2561PubMedCrossRef Hinselwood DC, Abrahamsen TW, Ekstrom PO (2005) BRAF mutation detection and identification by cycling temperature capillary electrophoresis. Electrophoresis 26(13):2553–2561PubMedCrossRef
20.
go back to reference Klein CA, Schmidt-Kittler O, Schardt JA, et al. (1999) Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci USA 96(8):4494–4499PubMedCrossRef Klein CA, Schmidt-Kittler O, Schardt JA, et al. (1999) Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci USA 96(8):4494–4499PubMedCrossRef
21.
go back to reference Fleming TP, Watson MA (2000) Mammaglobin, a breast-specific gene, and its utility as a marker for breast cancer. Ann N Y Acad Sci 923:78–89PubMedCrossRef Fleming TP, Watson MA (2000) Mammaglobin, a breast-specific gene, and its utility as a marker for breast cancer. Ann N Y Acad Sci 923:78–89PubMedCrossRef
22.
go back to reference Zehentner BK, Carter D (2004) Mammaglobin: a candidate diagnostic marker for breast cancer. Clin Biochem 37(4):249–257PubMedCrossRef Zehentner BK, Carter D (2004) Mammaglobin: a candidate diagnostic marker for breast cancer. Clin Biochem 37(4):249–257PubMedCrossRef
23.
go back to reference Sorlie T, Perou CM, Tibshirani R, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874PubMedCrossRef Sorlie T, Perou CM, Tibshirani R, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874PubMedCrossRef
24.
go back to reference van ‘t Veer LJ, Dai H, van de Vijver MJ, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536PubMedCrossRef van ‘t Veer LJ, Dai H, van de Vijver MJ, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536PubMedCrossRef
25.
go back to reference Ramaswamy S, Ross KN, Lander ES, et al. (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33(1):49–54PubMedCrossRef Ramaswamy S, Ross KN, Lander ES, et al. (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33(1):49–54PubMedCrossRef
26.
go back to reference Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3(6):453–458PubMedCrossRef Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3(6):453–458PubMedCrossRef
27.
go back to reference Leinung S, Wurl P, Weiss CL, et al. (2000) Cytokeratin-positive cells in bone marrow in comparison with other prognostic factors in colon carcinoma. Langenbecks Arch Surg 385(5):337–343PubMedCrossRef Leinung S, Wurl P, Weiss CL, et al. (2000) Cytokeratin-positive cells in bone marrow in comparison with other prognostic factors in colon carcinoma. Langenbecks Arch Surg 385(5):337–343PubMedCrossRef
28.
go back to reference Macadam R, Sarela A, Wilson J, et al. (2003) Bone marrow micrometastases predict early post-operative recurrence following surgical resection of oesophageal and gastric carcinoma. Eur J Surg Oncol 29(5):450–454PubMedCrossRef Macadam R, Sarela A, Wilson J, et al. (2003) Bone marrow micrometastases predict early post-operative recurrence following surgical resection of oesophageal and gastric carcinoma. Eur J Surg Oncol 29(5):450–454PubMedCrossRef
29.
go back to reference Pantel K, Izbicki J, Passlick B, et al. (1996) Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 347(9002):649–653PubMedCrossRef Pantel K, Izbicki J, Passlick B, et al. (1996) Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 347(9002):649–653PubMedCrossRef
30.
go back to reference Klein CA, Blankenstein TJ, Schmidt-Kittler O, et al. (2002) Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360(9334):683–689PubMedCrossRef Klein CA, Blankenstein TJ, Schmidt-Kittler O, et al. (2002) Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360(9334):683–689PubMedCrossRef
31.
go back to reference Schmidt-Kittler O, Ragg T, Daskalakis A, et al. (2003) From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 100(13):7737–7742PubMedCrossRef Schmidt-Kittler O, Ragg T, Daskalakis A, et al. (2003) From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 100(13):7737–7742PubMedCrossRef
32.
go back to reference Strumberg D, Richly H, Hilger RA, et al. (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43–9006 in patients with advanced refractory solid tumors. J Clin Oncol 23(5):965–972PubMedCrossRef Strumberg D, Richly H, Hilger RA, et al. (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43–9006 in patients with advanced refractory solid tumors. J Clin Oncol 23(5):965–972PubMedCrossRef
33.
go back to reference Sharma A, Trivedi NR, Zimmerman MA, et al. (2005) Mutant V599 EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65(6):2412–2421PubMedCrossRef Sharma A, Trivedi NR, Zimmerman MA, et al. (2005) Mutant V599 EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65(6):2412–2421PubMedCrossRef
34.
go back to reference Lynch TJ, Bell DW, Sordella R, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139PubMedCrossRef Lynch TJ, Bell DW, Sordella R, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139PubMedCrossRef
35.
go back to reference Paez JG, Janne PA, Lee JC, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497–1500PubMedCrossRef Paez JG, Janne PA, Lee JC, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497–1500PubMedCrossRef
Metadata
Title
Specific isolation of disseminated cancer cells: a new method permitting sensitive detection of target molecules of diagnostic and therapeutic value
Authors
Siri Tveito
Gunhild M. Maelandsmo
Hanne K. Hoifodt
Heidi Rasmussen
Oystein Fodstad
Publication date
01-09-2007
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 5/2007
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-006-9052-8

Other articles of this Issue 5/2007

Clinical & Experimental Metastasis 5/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine